Searched for
GENERIC PHARMACEUTICALS
Natco Pharma Q1 profit falls 57 pc to Rs 206.5 crNatco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalido...- Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEOGland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to h...
- Drug formulations & biologicals keep India's pharma exports healthy in Q1During the first quarter of fiscal 2027, India's pharmaceutical exports soared to $8.10 billion, showcasing remarkable strength in drug for...
- Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 croreZydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust ...
- Q1 Earnings Scorecard: Strong demand drives revenue, input costs hit profitsSustained market demand led to impressive revenue growth in the automotive and consumer goods sectors. In contrast, while the banking secto...
- Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- US cos see growing business interest in India as bilateral trade crosses $240 billion, says envoy GorSergio Gor, the US Ambassador, underscores the robust trust and teamwork that characterize US-India relations. With American businesses pur...
- Parl panel for early conclusion of India-US trade pact, tariff exemptions on key goodsThe panel suggested the commerce department prepare a time-bound roadmap to achieve the objectives of the Mission 500 initiative by promoti...
- Global Market: European shares climb as earnings, US-Iran diplomacy lift sentimentEuropean stocks advanced on Wednesday, driven by U.S.-Iran diplomatic talks. Mining companies led the rally as geopolitical concerns eased ...
- IPA seeks to regularise 'legacy' drugsThe Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examp...
- India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body saysIndia's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncer...
- Private equity firm Creador in talks to buy into generic drug co Leeford HealthPrivate equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acqu...
- Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...
- As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent PharmaceuticalsTorrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman...
- ChrysCapital acquires controlling 70.68% stake in Novartis India listed unit in first majority pharma investmentChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
Load More
